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Abstract
The pathobiology of Parkinson’s disease (PD) is associated with the loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) projecting to the striatum. Currently, there are no treatments that can halt or reverse the course of PD;
only palliative therapies, such as replacement strategies for missing neurotransmitters, exist. Thus, the successful brain
delivery of neurotrophic factors that promote neuronal survival and reverse the disease progression is crucial. We
demonstrated earlier systemically administered autologous macrophages can deliver nanoformulated antioxidant, catalase,
to the SNpc providing potent anti-inflammatory effects in PD mouse models. Here we evaluated genetically-modified
macrophages for active targeted brain delivery of glial cell-line derived neurotropic factor (GDNF). To capitalize on the
beneficial properties afforded by alternatively activated macrophages, transfected with GDNF-encoded pDNA cells were
further differentiated toward regenerative M2 phenotype. A systemic administration of GDNF-expressing macrophages
significantly ameliorated neurodegeneration and neuroinflammation in PD mice. Behavioral studies confirmed
neuroprotective effects of the macrophage-based drug delivery system. One of the suggested mechanisms of therapeutic
effects is the release of exosomes containing the expressed neurotropic factor followed by the efficient GDNF transfer to
target neurons. Such formulations can serve as a new technology based on cell-mediated active delivery of therapeutic
proteins that attenuate and reverse progression of PD, and ultimately provide hope for those patients who are already
significantly disabled by the disease.
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Introduction
An extraordinary goal, such as brain delivery of therapeutic
proteins, requires exceptional measures. The blood brain barrier
(BBB) is a major obstacle to the successful treatment of many
devastating diseases of central nervous system (CNS). Among them
are neurodegenerative disorders (PD, Alzheimer’s disease, and
amyotrophic lateral sclerosis [1–3]), infectious diseases (meningitis,
encephalitis, prion disease, and HIV-related dementia [4,5]),
stroke [6,7], and lysosomal storage diseases [8,9]. PD is the second
most common neurodegenerative disorder of people over 65 year
age; 70,000 new cases are registered in US every year.
Regrettably, no therapies are currently available that can
attenuate disease progression. The use of existing drugs provides
only symptomatic relief to patients that are hindered by the
development of drug resistance and progressive adverse side effects
such as motor complications and dyskinesia [10]. In addition, most
current therapies are based on pharmacological replacement of
lost striatal dopamine, which only masks or reduces the declining
dopaminergic activity in PD patients. Thus, novel therapies are
urgently required.
Disease symptoms are characterized by lack of neurotransmitter
dopamine due to the loss of dopaminergic neurons located in the
nigrostriatal system. A growing body of evidence indicates the
usefulness and efficacy of neurotrophic factors for the treatment of
PD [11–17]. It has been confirmed that BDNF expression levels
are decreased in the SNpc of PD patients [18]. Thus, the
neurotrophic factors, and in particular GDNF, can promote
regeneration of DA neurons and protect these cells from toxic
insults [19]. Furthermore, intracranial infusions of GDNF [20,21]
and BDNF [22] have been shown to provide protection and
restoration of DA neurons in rodent models of PD, and in 1-
methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)- or 6-hydro-
xydopamine (6-OHDA)-lesioned and intact aged primates
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[15,17,23–25]. Unfortunately, intracranial infusion is an invasive
procedure that carries a high risk of adverse effects. Thus, the
development of new drug delivery systems for neurotrophic factors
that can be administered systemically is crucial.
The majority of CNS disorders have in common an inflamma-
tory component [26] resulting in the excessive production of
reactive oxygen species (ROS) and subsequent neurodegeneration.
Immunocytes that include mononuclear phagocytes (dendritic
cells, monocytes and macrophages) exhibit an intrinsic homing
property of migrating toward the inflammation site via the
processes known as diapedesis and chemotaxis [27]. Thus,
immunocytes are reported to cause BBB breakdown following
brain inflammation [28–31] trafficking primarily between adjacent
endothelial cells, i.e. paracellulary through the junctional com-
plexes [32,33]. Considering that immunocytes readily home to the
sites with inflammation, we propose harnessing this natural
mechanism, and use macrophages for the active targeted delivery
of therapeutic proteins to the brain.
Two approaches are utilized in cell-mediated drug delivery.
First, host cells are loaded with a drug, usually incorporated into a
protective container, and then carry the drug to the disease side.
One of the main obstacles of this approach is efficient
disintegration of the entrapped foreign particles by monocytes.
Second, cell-carriers are genetically modified to produce thera-
peutically active molecules. For example, neurotropic factors, such
as glial cell-line derived neurotropic factor (GDNF), neurturin
(NTN), or vascular endothelial growth factor (VGEF) produced by
transfected neural stem cells (NSC) [34–36] and bone marrow-
derived macrophages and microglia [37,38] were used in PD
mouse models. In particular, bone marrow stem cells were
transduced ex vivo with lentivirus expressing a GDNF gene driven
by a synthetic macrophage-specific promoter and then transplant-
ed into recipient mice. Macrophage-mediated GDNF delivery
dramatically ameliorated PD-related inflammation and neuronal
degeneration in SNpc [37] resulting in axon regeneration and
reversed hypoactivity in mice. Furthermore, transfected NSC were
used for delivery of neurotrophic factors [39–43] in Alzheimer’s
disease mouse model.
Our earlier studies suggest cell-carriers offer distinct advantages
over standard drug administration regimens by providing disease-
specific homing, sustained on-site drug delivery, and improved
therapeutic efficacy [44–52]. Based on our previously developed
cell-mediated drug delivery system, present work utilized genet-
ically-modified autologous macrophages for active targeted
delivery of GDNF to the inflamed brain. The overall scheme of
these investigations is depicted in Figure 1. Macrophages were
transfected ex vivo to produce GDNF, and administered
intravenously in mice with PD model. This resulted in significant
increases in dopaminergic neurons survival and decreases in
inflammation in SNpc. Of note, genetically-modified macrophages
released exosomes with incorporated GDNF that may facilitate
GDNF transport into the target cells and preserve it against
degradation.
Exosomes are nanosized vesicles secreted by a variety of cells, in
particular, cells of the immune system: dendritic cells [53],
macrophages [54], B cells [55], and T cells [56]. These
extracellular vesicles were initially thought to be a mechanism
for removing unneeded proteins. Recent studies revealed, they are
actually specialized in long-distance intercellular communications
facilitating transfer of proteins [57], functional mRNAs and
microRNAs for subsequent protein expression in target cells
[58,59]. To shuttle their cargo, exosomes can attach by a range of
surface adhesion proteins and specific vector ligands (tetraspanins,
integrins, CD11b and CD18 receptors), and fuse with target
cellular membranes delivering their payload [53,60,61]. Indeed,
exosomes, comprised of cellular membranes, have an exceptional
ability to interact with target cells. Thus, we demonstrated here
that exosomes showed an extraordinary ability to abundantly
adhere and overflow neuronal cells as was visualized by confocal
microscopy. This mechanism may play a significant role in
GDNF-mediated protection effects, increasing the blood circula-
tion time, reducing immunogenicity, and facilitation of the protein
transfer across the BBB and into target neurons. In addition, the
membranotropic properties of GDNF-carrying exosomes may
facilitate GDNF binding to GFRa-1 receptors expressed on DA
neurons [62]. The present data indicate, intrinsic properties of
macrophages can overcome the limitations of current common
therapies, alleviate and reverse the symptoms, and may ultimately




The gWI high expression vectors encoding the reporter gene
green fluorescent protein (GFP) (gWIGFP) under control of an
optimized human cytomegalovirus (CMV) promoter followed by
intron A from the CMV immediate-early (IE) gene were used
throughout the study (Gene Therapy Systems, San Diego, CA).
Human GDNF cDNA (NM_199234) was provided by OriGene
(Rockville, MD). All plasmids are expanded in DH5a E.coli and
isolated using Qiagen endotoxin-free plasmid Giga-prep kits
(Qiagen, Valencia, CA) according to the supplier’s protocol.
Reagents
GenePORTER 3000 transfection agent was purchased from
AMS Biotechnology, England). Lipopolysaccharides (LPS), 6-
hydroxydopamine (6-OHDA), and Triton X-100 were purchased
from Sigma-Aldrich (St. Louis, MO, USA). A lipophilic fluores-
cent dye, 1,19-dioctadecyl-3,3,39,39-tetramethylindo-carbocyanine
perchlorate (DIL), was purchased from Invitrogen (Carlsbad, CA).
Interferon gamma (INT-c), and murine macrophage colony-
stimulating factor (MCSF) were purchased from Peprotech Inc
(Rocky Hill, NJ).
Cells
Raw 264.7, a mouse macrophage cell line, was purchased from
ATCC (cat # TIB-71), and cultured in Dulbecco’s Modified
Eagle’s Media (DMEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 2.5% horse serum and 15% FBS. Neuronal
PC12 rat adrenal pheochromocytoma cell line was obtained from
ATCC, and cultured in Dulbecco’s modified Eagle medium
(Hyclone, Utah, USA) supplemented with 10% FBS, and 1% (v/v)
of both penicillin and streptomycin. The cells were grown in an
incubator with optimal culture conditions of 37uC and 5% CO2,
and the medium was routinely replaced every 2–3 days.
Animals
BALB/C female mice (Charles River Laboratories, USA) eight
weeks of age were treated in accordance to the Principles of
Animal Care outlined by National Institutes of Health and
approved by the Institutional Animal Care and Use Committee of
the University of North Carolina at Chapel Hill.
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Transfection of Macrophages with GDNF-encoding pDNA
and Differentiation toward M2 Regenerative Subtype
Macrophages were incubated with a mixture of 13.6 mg GFP, or
GDNF pDNA and GenePORTER 3000 in serum free media for
four hours. Following incubation, an equal volume of full media
containing 20% FBS was added bringing final serum concentra-
tion to 10%. To exclude the possibility that cell death explains the
release of GDNF and GFP, percentage of live macrophages on the
fourth day after transfection was accounted by Fluorescence
Activated Cell Sorting (FACS). Transfected cells were collected,
washed, stained with Alexa 488 LIVE/DEAD dye according to
manufacturer’s protocol, and the amount of accumulated LIVE/
DEAD dye was assessed. The macrophage transfection efficiency
using GenePORTER 3000 reagent was around 40% as
determined by FACS for GFP-encoding pDNA [48].
To promote specific cell differentiation, Raw 264.7 macro-
phages were cultured in the presence of: (i) Interleukin 4 (IL-4) (to
promote M2 anti-inflammatory subtype); or (ii) Interferon gamma
(IFN-c) and LPS (to obtain M1 pro-inflammatory subtype). For
M2 subset differentiation, macrophages were supplemented with
IL 4 (20 ng/ml) for 48 hours. For M1 subset differentiation, the
cells were cultured in the mixture of IFN-c (20 ng/ml) and LPS
(100 ng/ml) for 48 hours. Following the incubation, media was
replaced with a mixture of antibodies to mannose receptor (M2
type marker, anti-CD 206, BD Bioscience, 1 mg/ml), and
antibodies to CD86 (M1 type marker, anti-CD 86, BD Bioscience,
2 mg/ml). The cells were incubated with the antibodies for 1 hour,
washed, fixed, and examined by confocal microscopy as described
below (CD 86, l= 405 nm, and CD 206, l= 647 nm). An
overexpression of specific markers related to M1 or M2 subset of
macrophages upon cell differentiation was confirmed by RT-PCR.
Isolation of Exosomes
Conditioned media from genetically-modified Raw 264.7
macrophages grown on T-75 flasks (206106 cells/flask) was
collected, and exosomes were isolated using ultra centrifugation
[53]. In brief, the culture supernatants were cleared of cell debris
and large vesicles by sequential centrifugation at 3006g for
10 min, 10006g for 20 min, and 10,0006g for 30 min, followed
by filtration using 0.2-mm syringe filters. Then, the cleared sample
was spun at 100,0006g for 1 hour to pellet the exosomes, and
supernatant was collected. The collected exosomes (1011–1012
exosomes/flask) were washed twice with PBS. To avoid contam-
ination of the FBS-derived exosomes, FBS was spun at 100,0006g
for 2 hours to remove exosomes before use. The recovery of
exosomes was estimated by measuring the protein concentration
using the Bradford assay and by Nanoparticle Tracking Analysis
(NTA). The obtained exosomal fraction was re-suspended in PBS
(500 ml, 1 mg/mL total protein), and characterized for size and
polydispersity by Dynamic Light Scattering (DLS) and Atomic
Force Microscopy (AFM). The obtained exosomal fraction was
evaluated for protein content.
Western Blot Analysis
Western blots were utilized to evaluate the presence of GDNF in
transfected macrophages as well as in exosomes secreted by
GDNF- or empty vector-transfected macrophages. Genetically-
modified macrophages and exosomes isolated from the condi-
tioned media were treated with lysis buffer (1% Triton X-100) and
protease inhibitors (Sigma) and protein concentration was
determined by BCA assay. Samples were mixed with 26SDS
sample buffer, boiled for 5 min and then separated on a precast 4–
20% SDS-PAGE gel (BioRad, USA). Proteins were transferred to
nitrocellulose membranes and GDNF was visualized with sheep
polyclonal antibodies to GDNF (Millipore, AB5252, 1:2000
dilution) and secondary antibodies donkey anti-sheep IgG-HRP
(Jackson ImmuneResearch; 1:5000 dilution). To correct for
loading differences in cellular lysates and exosomal fractions, the
levels of proteins were normalized to constitutively expressed b-
actin in cells with goat polyclonal antibodies to b-actin (Abcam,
ab8229; 1:500 dilution); and TSG101 in exosomes with goat
polyclonal antibodies to TSG101 (Santa Cruz, SC6037; 1:200
dilution). Furthermore, for the characterization of different
subtypes of polarized macrophages and released from them
exosomes, membranes with corresponding transferred protein
bands from macrophages or exosomes were blotted with rabbit
polyclonal antibodies to CD63 (Santa Cruz, SC15363; 1:200
dilution), iNOS (Santa Cruz, SC650; 1:200 dilution), Arg1 (Santa
Cruz, SC18351; 1:200 dilution) and CD206 (Santa Cruz, SC6037;
1:200 dilution) overnight at 4uC, and incubated with appropriate
HRP-conjugated secondary antibodies: goat anti-rabbit IgG-HRP
(Santa Cruz, SC2004; 1:2500 dilution), or donkey anti-goat IgG-
HRP (Santa Cruz, SC2020; 1:5000 dilution). Membranes were
washed and the expression levels were visualized with chemilumi-
nescent substrate (Thermo Scientific) and a FluorChem E imaging
Figure 1. Schematic representation of macrophage-mediated drug delivery approach. Autologous macrophages were transfected with
GDNF-encoding pDNA ex vitro and systemically administered into mice with brain inflammation. Driven by chemotaxis, genetically-modified cell-
carriers home the inflamed brain tissues, and deliver the expressed neurotrophic factor to the dopaminergic neurons protecting them from toxic
insults. The release of overexpressed GDNF in exosomes protected it against proteases degradation, facilitated the GDNF transfer into target neurons
and as a result, improved therapeutic efficacy of this drug formulation.
doi:10.1371/journal.pone.0106867.g001
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system (Protein Simple). Specific protein bands were quantitated
by densitometry (Bio-Rad Laboratories, Hercules, CA).
RT-PCR analysis
Total RNA of macrophages as well as exosomal RNA was
extracted using RNeasy mini kit (Qiagen, CA, USA) according to
manufacturer’s instructions. Residual genomic DNA of macro-
phages and exosomes was removed by incubating with Rnase-free
DNase set (Qiagen). RNA was analyzed and quantified using
nanodrop 2000c (Thermo Scientific, USA). As quality controls of
RNA samples purity from contaminating DNA and chaotropic
salts was obtained by absorbance Ratio A260/A280 and A260/
A230, respectively. RNA (1 mg) isolated from resting and polarized
macrophages cells and their respective exosomes was reverse
transcribed with Superscript III First-Strand synthesis system for
RT-PCR (Invitrogen, CA, USA) according to manufacturer’s
protocol. To quantify mRNA levels, quantitative reverse tran-
scription PCR was performed using an ABI StepOne Plus
Detection System (Applied Biosystems, MA, USA). TaqMan
PCR Universal Master Mix and Expression Assays were from
Applied Biosystems. Assay IDs: iNOS Mm00440502_m1, CD206
Mm00485148_m1 and CD63 Mm01966817_g1. CD63 was used
as exosomal marker and CD11b as macrophage cells marker.
Confocal Microscopy Studies
To visualize exosomal accumulation in target neurons, Raw
264.6 macrophages were transfected with GDNF-encoding DNA,
and cultured in exosome-free media for two days. Exosomes were
isolated from macrophage conditioned media by ultracentrifuga-
tion, and stained with the lipophilic fluorescent dye, DIL (red).
PC12 neurons were cultured with DIL-labeled exosomes or PLGA
nanoparticles (as a control) for three days, washed with PBS, and
stained with phallodin for actin microfilaments (green). The
accumulation levels were examined by confocal microscopy.
To track systemically injected macrophages in the inflamed
brain, macrophages were transfected with GFP-encoding DNA as
described above. For 6-OHDA intoxications, mice were stereo-
tactically injected with 6-OHDA solution (10 mg 6-OHDA in
0.9% NaCL with 0.02% ascorbic acid), flow rate of 0.1 mL/min
into the striatum (AP: +0.5; L: 22.0 and DV: 23.0 mm) [52].
Animals with brain inflammation induced were injected with
GFP-expressing Raw 264.7 macrophages on day twenty one after
intoxication with 6-OHDA via the intrajugular vein (i.v.). Two
days later, animals were sacrificed and perfused as described [52],
brains were removed, washed, post-fixed in 10% phosphate-
buffered paraformaldehyde, and evaluated by confocal microsco-
py.
Immunohistochemical and Stereological Analyses
6-OHDA-intoxicated mice were i.v. injected with PBS, or
GDNF-transfected macrophages, or macrophages transfected with
empty vector 48 hours after intoxication. Twenty four days later,
animals were sacrificed, perfused; brains were removed, washed,
post-fixed, and immunohistochemical analysis was performed in
30 mm thick consecutive coronal brain sections [46]. For detection
of microglia activation, tissue sections were incubated with
primary monoclonal rat anti mouse anti-CD11b antibodies
(AbD Serotec, Raleigh, NC) 1:500 dilution), and secondary
biotinylated goat anti-rat antibodies (Vector Laboratories, Burlin-
game, CA, 1:200 dilution). For the assessment of neuroprotection
effect, tyrosine hydroxylase (TH) staining was used to quantitate
numbers of dopaminergic neurons [63]. The total number of TH-
positive SN neurons and CD11b-positive microglia cells were
counted by using the optical fractionator module in StereoInves-
tigator software (MicroBrightField, Inc., Williston, VT) [46].
Figure 2. Expression of GDNF by genetically-modified macro-
phages. Raw 264.7 macrophages were pre-transfected with GDNF-
encoding pDNA and GenePorter 3000 reagent for 4 hours. Then,
exosomes were collected from concomitant macrophages media for
24 hours, and GDNF levels in cellular lysates (lines 2–3) and in exosomes
(lines 5–6) were examined by western blot. Commercially available
GDNF (line 1) served as a positive control. Significant amount of GDNF
was detected in the cells (line 3) and exosomes released from GDNF-
transfected macrophages (line 5), but not in macrophages transfected
with empty vector (line 2). Expressed GDNF was protected in exosomes
against degradation by pronase (line 5), while control GDNF was
degraded at these conditions (line 4). Destruction of exosomes by
sonication eliminated their protective effect (line 6). b-actin and TSG101
served as controls for cell lysates and exosomes, respectively.
doi:10.1371/journal.pone.0106867.g002
Figure 3. Effect of exosomes released from GDNF-transfected macrophages on the axonal growth in PC12 neurons. PC12 neurons
were cultured for 3 days in: (A) control media without GDNF; (B) in the presence of 100 ng/ml GDNF; or supplemented with (C) conditioned media
collected from GDNF-transfected macrophages; or (D) exosomes isolated from conditioned media released from GDNF-transfected macrophages.
Exosomes were fluorescently labeled with lypophilic dye, DIL (red) before the addition to the neurons (D). Following incubation, the cells were
washed with PBS, and stained with phallodin for actin microfilaments (green). Confocal images revealed the pronounced development of axons upon
treatment with media (C) and especially exosomes (D) released from GDNF-transfected macrophages. The bar: 20 mm.
doi:10.1371/journal.pone.0106867.g003
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Behavioral Tests
For the traditional constant speed rotarod test, mice were
trained and tested as previously described with slight modifications
[64]. 6-OHDA-intoxicated mice were i.v. injected with PBS, or
GDNF-transfected macrophages 48 hours after intoxication and
the latency to fall from the rotarod was determined at three speeds
(4, 5, and 7 rpm). Healthy mice i.c. injected with PBS were used as
a control [65]. For apomorphine test, the animals were injected
with apomorphine (0.05 mg / kg, s.c.) and rotations were scored
every 10 min for 90 min [66].
Statistical Analysis
For the all experiments, data are presented as the mean 6SEM.
Tests for significant differences between the groups in in vitro
experiments investigating transfection of macrophages, as well as
in in vivo evaluations of therapeutic effects of different drug
formulations were performed using a one-way ANOVA with
multiple comparisons (Fisher’s pairwise comparisons) using
GraphPad Prism 5.0 (GraphPad software, San Diego, CA,
USA). A standard T-test was performed when only two groups
(for example, for the evaluation of expression levels of specific
proteins by western blot) were compared. A minimum p value of
0.05 was chosen as the significance level for all tests.
Results
Exosomes secreted from genetically-modified
macrophages contain GDNF
The optimal conditions that provide for high levels and duration
of therapeutic proteins expression in macrophages identified
previously [48] were used to transfect Raw 264.7 macrophages.
Next, exosomes were collected from conditioned macrophages
Figure 4. Differentiation of macrophages toward ‘‘alternatively’’ activated M2 subtype. Raw 264.7 macrophages were cultured in the
presence of: (A) Interferon gamma (IFN-c) and lipopolysaccharides (LPS) for M1 pro-inflammatory subtype; or (B)) Interleukin 4 (IL 4) for M2 anti-
inflammatory subtype for two days as described in Materials and Methods section. Then, the cells were stained with a mixture of antibodies to CD
86 (green) and mannose receptor CD206 (red) for M1 and M2 phenotype, respectively, and examined by confocal microscopy. Macrophages
differentiated in the presence of INF-c/LPS showed high expression of CD86, but low if any mannose receptor levels indicating classically activated
M1 subtype (A). In contrast, cells differentiated in the presence of IL-4 showed high expression of mannose receptor, and low expression of CD 86
that is attributed to M2 macrophages (B). Non-differentiated Mo macrophages served as a control (C). Bar: 10 mm. RT-PCR studies confirmed
statistically significantly elevated levels of inducible Nitric Oxide Synthases (iNOS) mRNA in M1 cells, and high levels of CD206 and Arginase 1 (Arg1)
mRNA in M2 macrophages (D), compared to Mo macrophages (p,0.05).
doi:10.1371/journal.pone.0106867.g004
Figure 5. Characterization of exosomes released from differentiated subtypes of macrophages. Exosomes were isolated from
conditional media of differentiated macrophages and examined for the presence of specific markers by RP-PCR (A) and western blot (B). Expression
of Arg1 and CD206 mRNA and protein (markers for M2 subtype) was detected in exosomes originated from M2 macrophages, but not in those
secreted from M1 macrophages. In contrast, expression of iNOS mRNA and protein was detected in exosomes released from M1 macrophages, but
not in those secreted by M2 macrophages. TSG101 was used as house-keeping protein for exosomes. Values are means 6SEM (N = 4), and p,0.05
compared with the expression levels in Mo macrophages.
doi:10.1371/journal.pone.0106867.g005
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media for 24 hours, and the expression of the encoded protein in
the in cellular lysates and exosomes were evaluated by western blot
(Fig. 2). Significant amounts of GDNF was detected in the cells
(line 3) and exosomes released from GDNF-transfected macro-
phages (line 5), but not in macrophages transfected with empty
vector (line 2). Noteworthy, the expressed GDNF was protected in
exosomes against degradation by pronase (line 5); while control
GDNF was degraded at these conditions (line 4). Destruction of
exosomes by sonication eliminated their protective effect against
proteases degradation (line 6). The average size for exosomes
released from GDNF-transfected macrophages (96.069.1 nm) was
slightly greater than those released from non-transfected macro-
phages (90.563.4 nm).
Effects of GDNF-transfected Macrophages on axonal
growth in vitro
A profound therapeutic effect of GDNF released from pre-
loaded M2 macrophages in vitro was demonstrated in PC12
neurons that are known to express GDNF receptor (Fig. 3).
Neurons were cultured for 72 hours in: (A) control media without
GDNF; (B) media supplemented with high concentration of
commercially available GDNF (100 ng/ml); (C) conditioned
media collected from GDNF-transfected macrophages, or (D)
exosomes isolated from GDNF-transfected macrophages. Follow-
ing the incubation, the cells were stained with phallodin for actin
microfilaments (green) and DAPI for cell nucleus (blue). In
parallel, exosomes were stained with a lipophilic fluorescent dye,
DID (red). Confocal images revealed the significant axonal growth
in neurons cultured with conditioned media from GDNF-
preloaded macrophages (Fig. 3 C) suggesting GDNF was released
from the cell-carriers in a functional state. Noteworthy, treatment
of PC12 neurons with exosomes released from pre-transfected
macrophages resulted in the drastic increase of neuronal
maturation with a pronounced outgrowth of axons and dendrites
(Fig. 3 D). The effects were greater than those caused by a high
dose of commercially-available GDNF (Fig. 3 B). It is likely,
similar to catalase-transfected macrophages [48], exosomes with
incorporated overexpressed neurotropic factor promote GDNF
transfer, and secure its efficient accumulation and favorable
intracellular localization in target neurons.
Differentiation of Macrophages and Using an
Alternatively Activated Neuroregenerative M2 Subtype
To enhance the therapeutic effects of GDNF and avoid the pro-
inflammatory neurotoxic effects of classically-activated M1 mac-
rophages [67], Raw 264.7 macrophages were differentiated to M2
regenerative subtype. For this purpose, macrophages were
cultured in the presence of Interleukin 4 (IL 4) for M2 subtype;
or Interferon gamma (IFN-c) and lipopolysaccharides (LPS), as a
negative control for M1 pro-inflammatory subtype. The obtained
subsets of macrophages were characterized by confocal microsco-
py (Fig. 4 A–C) and RT-PCR (Fig. 4 D). Mannose receptor
(CD206), and Arginase 1 (Arg1) were chosen as principal markers
form identifying M2 macrophages subtype. Levels of inducible
Nitric Oxide Synthases (iNOS, CD86) were examined as marker
of M1 macrophages subtype. Noteworthy, Arg1 and iNOS [68]
were demontrated to have anti-inflammatory and pro-inflamma-
tory properties, respectively.
Macrophages differentiated in the presence of INF-c/LPS
demonstrated considerable expression of CD 86, and low, if any,
levels of mannose receptor (Fig. 4 A) that is indicative for
classically activated pro-inflammatory M1 subtype. In contrast,
Raw 264.7 macrophages differentiated in the presence of IL-4
showed high expression levels of mannose receptor, and low, if
any, expression of CD 86 (Fig. 4B) that indicative for ‘‘alter-
natevly activated’’ anti-inflammatory macrophages. Non-activated
Mo macrophages showed low, if any expression of both CD86 and
CD206 receptors (Fig. 4 C). Noteworthy, the polarization to
different macrophages subtypes altered the cells morphology. RT-
PCR studies confirmed elevated levels of iNOS mRNA in M1
cells, and high levels of CD206 and Arginase 1 (Arg1) mRNA in
M2 macrophages (Fig. 4 D).
Next, we hypothesized that exosomal content, at least in part,
should reflect the content of parental macrophages. Thus,
exosomes released from M2 macrophages may exhibit neuropro-
tective and regenerative properties by themselves. A presence of
Arg1 mRNA and Arg1 protein that indicative for M2 macro-
phages subtype was evaluated by RT-PCR (Fig. 5 A) and western
blot analyses (Fig. 5 B). The obtained data confirmed exosomes
secreted by M2 regenerative macrophages, but not M1 pro-
inflammatory macrophages showed high levels of Arg1 and
CD206 mRNA and Arg1 protein. In contrast, expression of
iNOS mRNA and protein (marker for M1 macrophages) was
detected in exosomes released from M1 macrophages, but not in
those secreted by M2 macrophages. Noteworthy, although the
overall trend of the expression of specific markers in different
subtypes macrophages and exosomes is analogous, these levels
might not be completely the same, as exosomes should reflect, but
not copy the content of parental macrophages they were released
from. This approach was utilized further to differentiate the cell-
carriers towards the M2 phenotype prior to the infusion to
capitalize on the beneficial properties afforded by alternatively
activated M2 macrophages in the context of PD, and minimize the
potential of the cells converting to the pro-inflammatory M1
subtype.
Figure 6. Recruitment of GFP-expressing M2 macrophages to
SNpc in 6-OHDA-intoxicated mice. Macrophages were transfected
with GFP-encoding pDNA as described in Materials and Methods
section and stained with primary antibodies to CD206, a marker for M2
macrophages, and secondary fluorescently-labeled anti-Mouse-IgG-atto
647N (red). BALB/c mice were i.c. intoxicated with 6-OHDA into SNpc.
Twenty one day later, the animals were i.v. injected with GFP-expressing
RAW 264.7 macrophages (green, 56106 cells/ mouse in 100 ml). Twenty
four hours later mice were sacrificed, and perfused with PBS and 4%
PFA. Brains were frozen, sectioned with a cryostat (10 mm thick), and
examined by confocal microscopy (606magnification) (A, B). Healthy
mice without brain inflammation (with PBS i.c. injections) were used as
a control group (C). Slides were stained with for expression of mannose
receptor (CD206 antibodies). Co-localization of GFP-expressing macro-
phages and CD206 antibodies to mannose receptor manifested in
yellow staining (arrows) confirmed presence of significant amounts of
the M2 genetically-modified cells in the intoxicated brain endothelial
microvesseles (A), and parenchyma (B). No fluorescence in the healthy
brain was found (C) indicating that systemically administered Raw 264.7
macrophages did not cross the BBB in the absence of brain
inflammation. The bar: 20 mm.
doi:10.1371/journal.pone.0106867.g006
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Systemically-administered M2 Macrophages Home
Inflamed Brain Tissues and Sustain their Phenotype in
Brain Tissues
Raw 264.6 macrophages were transfected with GFP-encoding
pDNA, and then differentiated to M2 regenerative subtype as
described above. BALB/c mice were i.c. intoxicated with 6-
OHDA into SNpc. Twenty one days later (at the pick of
inflammation), mice were systemically injected with GFP-express-
ing macrophages (56106 cells/ mouse in 100 ml). Twenty four
hours later, the mice were sacrificed, and perfused with PBS and
4% PFA. Healthy mice without brain inflammation were used as a
control group. Brain slides were stained with primary antibodies to
CD 206, a marker for mannose receptor attributed to M2 subtype
of macrophages. Confocal images of brains sections indicate
systemically infused macrophages home the inflamed brain and
localize around brain endothelial microvesseles (Fig. 6 A), and
parenchyma (Fig. 6 B). Co-localization of GFP-expressing
macrophages (green) and CD206 staining (red) manifested in
yellow confirmed, the macrophages sustain their M2 phenotype in
the intoxicated brain. No macrophages were found in healthy
brain (Fig. 6 C) indicating the cells do not cross the BBB in the
absence of inflammation.
Macrophage-mediated Neuroprotection in PD mice
A potent neuroprotective effect of GDNF-transfected macro-
phages was demonstrated in the 6-OHDA-intoxicated mice
(Fig. 7). GDNF-overexpressing Raw 264.7 macrophages were
systemically administered to BALB/c mice with brain inflamma-
tion (16106 cells/100 ml) 48 hours after i.c. intoxication with 6-
OHDA (PD mouse model). Non-intoxicated mice were used as
healthy controls. 21 day later, mice were sacrificed, perfused, and
the brain slides were stained for tyrosine hydroxylase (TH)-
expressing DA neurons. I.c. intoxications of 6-OHDA caused
substantial neurodegenreation in the SNpc (Fig. 7 C, Table 1)
compared to healthy mice (Fig. 7 A, Table 1). Systemic
administration of GDNF-transfected macrophages protected DA
neurons against 6-OHDA intoxications (Fig. 7 E, Table 1). The
numbers of TH+ neurons in SNpc of 6-OHDA animals treated
with GDNF-transfected macrophages were significantly (p,0.05)
greater than those 6-OHDA intoxicated, and then PBS-injected
animals (Table 1). Noteworthy, empty-transfected macrophages
slightly improved neuronal survival in PD animals, probably due
to their regenerative M2 subtype, although this effect was not
statistically significant (Fig. 7D, Table 1). Indeed, empty-trans-
fected macrophages did not affect neuronal survival in healthy
mice (Fig. 7 B, Table 1). This signifies that GDNF-transfected
macrophages can efficiently protect DA neurons against 6-
OHDA-induced intoxication. The therapeutic effect of GDNF-
transfected macrophages was also manifested in significant
decreases in inflammation and levels of activated microglia in
SNpc (Figure 8, Table 1).
Finally, behavioral tests demonstrated statistically significant
improvements in motor functions upon treatment with GDNF-
transfected macrophages (Fig. 9). Specifically, the loss of dopa-
minergic input due to the lesion of the left nigro-striatial pathway
resulted in number of full-body contralateral rotations induced by
a dopaminergic agent, apomorphine (Fig. 9 A). In contrast,
systemic administration of genetically-modified macrophages to 6-
OHDA intoxicated mice drastically (p,0.005) reduced number of
Figure 7. Neuroprotective effects of GDNF-transfected macrophages in PD mouse model. BALB/c mice were i.c. injected with 6-OHDA.
Forty eight hours later, animals were i.v. injected with GDNF-transfected or empty-transfected macrophages, or PBS, and 21 days later they were
sacrificed, and mid-brain slides were stained for expression of TH, a marker for dopaminergic neurons. Whereas 6-OHDA treatment caused significant
neuronal loss in SNpc (red arrow), administration of GDNF-transfected macrophages dramatically increased neuronal survival (blue arrow).
Administration of empty-vector transfected macrophages did not affect the number of dopaminergic neurons in healthy mice, and shows mild effect
on increased neuronal survival in PD mice (white arrow).
doi:10.1371/journal.pone.0106867.g007
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these rotations on the seventh week following the intoxication in
apomorphine test to the levels of the non-intoxicated animals.
Furthermore, the motor functions were preserved by systemic
administration of GDNF-transfected macrophages in 6-OHDA
intoxicated animals at the levels similar to those of control non-
intoxicated mice, as demonstrated in rotarod test (Fig. 9 B).
Discussion
A long-term objective of these investigations is to develop an
active targeted cell-mediated delivery of therapeutic proteins to the
brain. We demonstrated here that genetically-modified macro-
phages can produce therapeutically-active neurotrophic factor,
GDNF, and release it in extracellular vesicles, exsosomes. The
most important finding of this work is that GDNF-transfected
macrophages provide significant neuronal protection in a PD
mouse model. Our in vivo experiments demonstrated that
systemically administered GDNF-expressing macrophages migrate
across the BBB towards the inflammation site in large numbers,
and provide efficient sustained delivery of their drug payload at the
disease site that is consistent with previously reported findings [45–
49]. To enforce outcomes of the new formulation, a specific subset
of ‘‘alternatively activated’’ (M2) macrophages with regenerative
functions was used. Thus, macrophages, polarized to M2
regenerative subtype, represent biologically-active carriers that
can promote neuronal regeneration enhancing the therapeutic
efficacy of drug formulations.
Figure 8. GDNF-transfected macrophages reduce neuro-inflammation in PD mice. BALB/c mice were i.c. injected with 6-OHDA. Forty eight
hours later, animals were i.v. injected with GDNF-transfected or empty-transfected macrophages, or PBS, and 21 days later they were sacrificed, and
mid-brain slides were stained for expression of CD11b, a marker for activated microglia. A 6-OHDA-mediated intoxication up-regulated expression of
CD11b by microglia within the SNpc as exhibited a more amoeboid morphology in 6-OHDA-treated mice compared to ramified microglia in PBS-
treated mice. In contrast, treatment of 6-OHDA-intoxicated mice with GDNF-transfected macrophages resulted in the decreased levels of CD11b
compared with 6-OHDA-intoxicated control animals. Administration of empty-vector transfected macrophages did not affect the number of
dopaminergic neurons in PD or healthy mice.
doi:10.1371/journal.pone.0106867.g008
Table 1. Effect of GDNF-transfected macrophages on inflammation and neurodegeneration in mice with PD modela.
Treatment CD11b+ (cells per mm
2) Total N of neurons b 6103
PBS 6-OHDA PBS 6-OHDA
PBS 10.161.2 90.0611 (**)c 5.961.4 2.1560.3 (**)
GDNF-transfected macrophages n/a 63.565.2 (*) n/a 3.360.6 (*, #)
Empty-transfected macrophages 9.861.0 87.0611.1 5.761.5 2.560.7
aBALB/c mice were i.c. injected with 6-OHDA. Forty eight hours later, the animals were i.v. injected with various macrophage-based formulations or PBS. A control group
was i.c. injected with PBS, and then 48 hours later i.v. injected with PBS.
bTotal number of neurons was calculated in ipsilateral hemisphere.
cStatistical significance is shown by asterisk: p,0.05 (*), and p,0.005 (**) compared to mice with i.c. PBS injections followed by i.v. PBS injections (healthy controls); or
p,0.05 (#), compared to mice with i.c. 6-OHDA injections followed by i.v. PBS injections (PD controls). Errors are mean 6SEM, N = 7.
doi:10.1371/journal.pone.0106867.t001
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The mechanism of the macrophage-mediated drug delivery is
not fully understood. Thus, several independent processes may
serve to improve GDNF-expressing macrophage therapeutics. In
addition to the targeted tissue-specific delivery of therapeutics in
macrophages [46,52], drug-carrying macrophages were shown to
increase time circulation in the blood, and therefore permit
sustained release of the therapeutic protein allowing the drug to
enter the brain, independent of carrier cells (‘‘depot effect’’)
[46,52]. Furthermore, we reported earlier that significant catalase
transport across the BBB can be attributed to the efficient
interaction of exosomes with brain microvessel endothelial cells
followed by facilitated protein transfer to the brain [47]. Similar
mechanism may be employed in the GDNF transfer from carrier
macrophages across the BBB. We demonstrated that exosomes
secreted from preloaded with nanoformulated catalase macro-
phages attach to the plasma membranes, and discharge their cargo
into target cells [47]. As a result, the drug-incorporated
nanoparticles were transferred from macrophages to adjacent
cells, and diffused broadly throughout the recipient cells avoiding
degradation in lysosomes. This mechanism enabled the drug to
reach different intracellular compartments such as mitochondria,
cytoplasm, and endoplasmic reticulum, and produce a powerful
therapeutic effects [47]. Indeed, the mechanism of GDNF action
differs from catalase neuroprotective effects, as specific binding to
GFRa-1 receptors is required in order to accomplish GDNF-
mediated neuroprotection. Nevertheless, we hypothesized that the
efficient interactions of exosomal carriers with plasma membranes
of DA neurons may facilitate GDNF binding to their receptors,
and result in the profound therapeutic effect. Unfortunately, at this
stage of understanding, we cannot discriminate, which mechanism
is the most important for the therapeutic effects of cell-based
formulations. A comprehensive examination and detailed under-
standing of these mechanisms would be of great value in designing
strategies for cell-mediated drug delivery.
Several trials human and nonhuman (primate) were initiated to
evaluate efficiency of GDNF for PD treatment as well as its off-side
effects. Thus, GDNF showed therapeutic promise when injected
intracranially through a surgically implanted shunt [69–71].
Although there were significant improvements followed GDNF
infusions, some primate subjects revealed damage in the cerebel-
lum found in brain autopsies. This was attributed to the rapid
withdrawal from large amounts of GDNF and damaging tissues by
the catheter, rather than to the direct GDNF toxic effects [71]. To
this end, we believe that cell-mediated GDNF delivery can
eliminate these issues, providing continuous targeted GDNF
delivery specifically to the inflamed brain areas. Using genetical-
ly-modified macrophages as a cell-mediated drug delivery system
will target the therapeutic proteins to the brain, prolong drug half-
live, and diminish drug immunogenicity. In addition, properly
differentiated immune cells accumulating in traumatic, degener-
ative, ischemic, infectious, and autoimmune lesions of the nervous
system might provide a neuroprotective effect, which may further
boost the therapeutic effect of cell-mediated drug delivery systems.
It is anticipated that these studies will lead to the developing a new
technology based on active targeted cell-mediated delivery of
therapeutic polypeptides that produce neuroprotection and
neuroregeneration in patients with PD.
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Figure 9. GDNF-transfected macrophages significantly improved motor functions in PD mouse model. 6-OHDA-intoxicated BALB/c
mice were i.v. injected with GDNF-transfected macrophages (white bars), or PBS (black bars) 48 hours after the intoxication. A control group (grey
bars) was i.c. injected with PBS, and then 48 hours later i.v. injected with PBS. Apomorphine (A) and rotarod (B) tests demonstrated statistically
significant improvements in motor functions upon treatment with GDNF-carrying macrophages. Values are means 6SEM (N = 12), and p,0.05
compared with 6-ODHA-intoxicated mice.
doi:10.1371/journal.pone.0106867.g009
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